## 3 Results
### Sensitivity and Specificity of ARFI Measurements  
Data on ARFI were successfully obtained by two-location measurements from all patients. The diagnostic performance of ARFI and serum fibrosis markers for liver fibrosis was assessed using ROC curves. According to the data on two-location measurements, ARFI values measured at Location A or B, mean values of Locations A and B, and higher or lower ARFI data between Locations A and B were examined separately. \begin{table}
\begin{tabular}{c c c c} \hline \hline
**Category** & **Non-Treatment** & **Treatment** & \(p\)**Value \#** \\ \hline Total No & 112 & 34 & \\ Age (year) & 52.34 \(\pm\) 10.80 & 55.05 \(\pm\) 10.41 & \\ Male (\%) & 85 (75.9) & 28 (82.4) & \\ Liver cancer (\%) & 55 (49.1) & 19 (55.9) & \\ Ultrasound spleen index (cm\({}^{2}\)) & 16.58 \(\pm\) 7.10 & 16.84 \(\pm\) 5.80 & \\ Ultrasound fibrosis score & 6.43 \(\pm\) 1.38 & 7.26 \(\pm\) 1.05 & 0.001 \\ GGT (glutamyl transeptidase) (U/L) & 60.9 \(\pm\) 71.68 & 56.48 \(\pm\) 53.90 & \\ AST (U/L) & 73 \(\pm\) 111 & 49 \(\pm\) 48 & \\ ALT (U/L) & 92 \(\pm\) 193 & 56 \(\pm\) 75 & \\ Bilirubin (mg/DL) & 0.97 \(\pm\) 1.22 & 0.76 \(\pm\) 0.36 & \\ Platelet (10\({}^{9}\)/L) & 187.33 \(\pm\) 65.10 & 161.62 \(\pm\) 47.52 & 0.034 \\ Prothrombin time (\({}^{*}\) INR) & 1.07 \(\pm\) 0.08 & 1.08 \(\pm\) 0.06 & \\ Body height (cm) & 164.56 \(\pm\) 7.51 & 164.81 \(\pm\) 10.47 & \\ Body weight (kg) & 69.38 \(\pm\) 10.47 & 69.45 \(\pm\) 13.30 & \\ Histology & & & \\ [PERSON] inflammatory score & 3.89 \(\pm\) 2.45 & 2.76 \(\pm\) 1.74 & 0.020 \\ Confidence necrosis (No.) & 3 (2.7) & 1 (2.9) & \\ Metavir fibrosis score 0 & 3 (2.7) & 0 (0) & \\ Metavir fibrosis score 1 & 12 (10.7) & 2 (5.9) & \\ Metavir fibrosis score 2 & 43 (38.4) & 5 (14.7) & \\ Metavir fibrosis score 3 & 30 (26.8) & 13 (38.2) & \\ Metavir fibrosis score 4 & 24 (21.4) & 14 (41.2) & 0.026 \\ \hline \hline \end{tabular}  
* Number in the parenthesis is percentage of total cases. \({}^{*}\) INR = international normalized ratio; # Univariate analysis, not significant after multivariate analysis.  
\end{table} 
Table 1: Demographic and laboratory data with or without anti-HBV therapy. For comparison with ARFI parameters, data on APRI and FIB4 were combined in the ROC curve analysis. The results are listed in Figure 1 for patients without anti-HBV therapy and in Figure 2 for patients with anti-HBV therapy. The ARFI-related parameters have significantly higher area under the ROC (AUROC) curve than APRI or FIB4 in both treatment and non-treatment groups. Figure 1: The areas under the receiver-operating characteristic (AUROC) of acoustic radiation force impulse (ARFI) values, APRI, and fibrosis-4 score (FIB4) for prediction of liver cirrhosis in patients with chronic hepatitis B without anti-HBV therapy. A higher AUROC is found in ARFI-related parameters (0.813\(\sim\)0.826) than in APRI (0.664) or FIB4 (0.712) (Aymptotic 95% CI: Asymptotic 95% Confidence Intervals; a Standard Error; b Asymptotic \(p\) value). Figure 2: The AUROC of ARFI values, APRI, and FIB4 for prediction of liver cirrhosis in patients with chronic hepatitis B with anti-HBV therapy. A higher AUROC is found in ARFI-related parameters (0.737\(\sim\)0.823) than in APRI (0.482) or FIB4 (0.514) (Aymptotic 95% CI: Asymptotic 95% Confidence Intervals; a Standard Error; b Asymptotic \(p\) value). According to the results of AUROC analysis, the cut-off values for the prediction of liver cirrhosis on each parameter are listed in Table 2. Among the ARFI parameters, lower ARFI shows the highest AUROC curve (0.827) in non-treatment groups, whereas higher ARFI shows the highest AUROC curve (0.823) in the treatment group. To simplify the cut-off system, we use mean ARFI in both treatment and non-treatment groups. The AUROC for the diagnosis of Metavir F4 by mean ARFI is 0.820 [standard error of mean (SE) 0.048, (confidence intervals (CI): 0.725; 0.913) Figure 1] in the non-treatment group.